Clinical Research Directory
Browse clinical research sites, groups, and studies.
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
Sponsor: Fudan University
Summary
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance? Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not. Participants will: 1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.
Official title: Postoperative Adjuvant Treatment for Thymic Cancer With Completed Resection (Radiotherapy vs Chemoradiotherapy): A Prospective, Multicenter, Open-label, Phase III, Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
172
Start Date
2024-04-09
Completion Date
2030-05-01
Last Updated
2024-05-10
Healthy Volunteers
No
Conditions
Interventions
Chemotherapy
paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
Radiotherapy
IMRT, 50Gy/25f
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China